Menu
Jonathan Hepple
Managing Partner
Jon Hepple is a co-founder of Rosetta with more than 20 years’ investment experience in the life sciences industry. Jon started his investment career at Rothschild Asset Management and later became a partner at Seroba Life Sciences, where he held board positions at Covagen and Opsona. In addition to Rosetta, Jon is also a Senior Advisor to Oxford Science Enterprises and holds a PhD from Cambridge University.
Jon has held Board roles and is actively engaged in portfolio companies such as Aprea Therapeutics, Catalyst Biosciences, GlycoMimetics, Novimmune, Paratek and Tranzyme, and also has worked closely with GeminX, Polyphor and Zealand. He currently serves on the Boards of Carrick Therapeutics, Nucleome Therapeutics and Mission Therapeutics.
Meet more of our people
